Key Points
- Financial Lp Hrt made back-to-back purchases — 74,350 shares on April 14 at $0.77 ($57,249.50) and 92,554 shares on April 15 at $0.76 ($70,341.04) — significantly increasing its stake, with the April 14 trade reported as a 246.62% ownership rise to 104,498 shares; both trades were disclosed in SEC filings.
- Onconetix is a tiny-cap biotech trading around $0.76 per share with a market capitalization of approximately $498,560, offering men's‑health and oncology products (including FDA‑approved Entadfi and Proclarix) and showing high volatility (1‑year range $0.67–$74.29; institutional ownership ~23.9%).
Onconetix, Inc. (NASDAQ:ONCO - Get Free Report) major shareholder Financial Lp Hrt acquired 74,350 shares of the firm's stock in a transaction on Tuesday, April 14th. The shares were bought at an average cost of $0.77 per share, for a total transaction of $57,249.50. Following the acquisition, the insider owned 104,498 shares in the company, valued at approximately $80,463.46. The trade was a 246.62% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Large shareholders that own more than 10% of a company's shares are required to disclose their sales and purchases with the SEC.
Financial Lp Hrt also recently made the following trade(s):
- On Wednesday, April 15th, Financial Lp Hrt bought 92,554 shares of Onconetix stock. The stock was bought at an average cost of $0.76 per share, with a total value of $70,341.04.
Onconetix Trading Down 0.2%
Shares of ONCO stock opened at $0.76 on Friday. Onconetix, Inc. has a 1 year low of $0.67 and a 1 year high of $74.29. The firm's 50 day moving average is $2.96 and its 200-day moving average is $8.92. The firm has a market capitalization of $498,560.00, a price-to-earnings ratio of 0.00 and a beta of 3.63.
Institutional Inflows and Outflows
An institutional investor recently bought a new position in Onconetix stock. Pacific Capital Wealth Advisors Inc. acquired a new stake in Onconetix, Inc. (NASDAQ:ONCO - Free Report) during the third quarter, according to its most recent filing with the SEC. The firm acquired 13,000 shares of the company's stock, valued at approximately $40,000. Pacific Capital Wealth Advisors Inc. owned about 0.84% of Onconetix as of its most recent filing with the SEC. Institutional investors and hedge funds own 23.89% of the company's stock.
Onconetix Company Profile
(
Get Free Report)
Onconetix, Inc, a biotechnology company, focuses on the research, development, and commercialization of solutions for men's health and oncology. It offers Entadfi, an FDA-approved, once daily pill that combines finasteride and tadalafil for the treatment of benign prostatic hyperplasia; and Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer. The company was formerly known as Blue Water Biotech, Inc and changed its name to Onconetix, Inc in December 2023. Onconetix, Inc was incorporated in 2018 and is headquartered in Cincinnati, Ohio.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
